Emerging treatments for urinary incontinence

Bibliography

• Abrams P, Andersson K, Brubaker L, et al. Recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. In: Chapple C. editor, 3rd international consultation on incontinence. International Continence Society ICoUD, Societe International d'Urologie, Monaco; 2005
   Google Scholar
• Abrams P, Andersson K, Birder L, et al. Fourth international consultation on incontinence recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010;29:213-40
   PubMed Web of Science ®Google Scholar
• Melville J. Urinary incontinence in US women: a population-based study. Arch Intern Med 2005;165:537-42
   PubMed Web of Science ®Google Scholar
• Hagglund D, Walker-Engstrom M, Larsson G, et al. Reasons why women with long-term urinary incontinence do not seek professional help: a cross-sectional population-based cohort study. Int Urogynecol J Pelvic Floor Dysfunct 2003;14:296-304
   PubMed Web of Science ®Google Scholar
• Claxton A, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296-310
   PubMed Web of Science ®Google Scholar
• Goeschen K. Can motor urge incontinence be surgically cured? Pelviperineology 2007;26(1):41-2
   Google Scholar
• Nguyen J. Resolution of motor urge incontinence after surgical repair of pelvic organ prolapse. J Urol 2001;166:2263-6
   PubMed Web of Science ®Google Scholar
• Petros P, IUlmsten U. An integral theory and its method for the diagnosis and management of female urinary incontinence. Scand J Urol Nephrol Suppl 1993;153:1-93
   PubMedGoogle Scholar
• Litwin MS, Saigal CS, Yano EM, et al. Urologic diseases in America Project: analytical methods and principal findings. J Urol 2005;173:933-7
   PubMed Web of Science ®Google Scholar
• Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004;63:461-5
   PubMed Web of Science ®Google Scholar
• Subak L, Brown J, Kraus S, et al. The “costs” of urinary incontinence for women. Obstet Gynecol 2006;107:908-16
   PubMed Web of Science ®Google Scholar
• Chapple C. Urinary incontinence: oxybutynin topical gel for overactive bladder. Nat Rev Urol 2009;6:351-2
   PubMed Web of Science ®Google Scholar
• Mock S, Dmochowski R. Evaluation of fesoterodine fumarate for the treatment of an overactive bladder. Expert Opin Drug Metab Toxicol 2013;9:1659-66
   PubMed Web of Science ®Google Scholar
• Callegari E, Malhotra B, Bungay P, et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 2011;72:235-46
   PubMed Web of Science ®Google Scholar
• Kurizaki Y, Ishizuka O, Imamura T, et al. Relationship between expression of beta3-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Neurourol Urodyn 2013;32:88-91
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - efficacy results from a phase 2 study (SYMPHONY). J Urol 2013;189(Suppl):1958
   Google Scholar
• Chapple C, Kaplan S, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta3-adrenoceptor agonist, in overactive bladder. J Urol 2013;63:296-305
   Google Scholar
• Popat R, Apostolidis A, Kalsi V, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botilinum-a toxin. J Urol 2005;174:984-9
   PubMed Web of Science ®Google Scholar
• McVary K, Monnig W, Camps J Jr. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007;177:1071
   PubMed Web of Science ®Google Scholar
• McVary K, Roehrborn C, Kaminetsky J. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401
   PubMed Web of Science ®Google Scholar
• Stief C, Porst H, Neuser D. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236-44
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Roehrborn C, Klise S. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 2013;189(1 Suppl):S135-40
   PubMed Web of Science ®Google Scholar
• Füllhase C, Hennenberg M, Giese A. Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity. J Urol 2013;190:1430
   PubMed Web of Science ®Google Scholar
• Alhasso A, Glazener C, Pickard R, et al. Cochrane review: adrenergic drugs for urinary incontinence in adults. Cochrane Libr. 2010;(12)
   Google Scholar
• Mariappan P, Ballantyne Z, N'Dow JM, et al. Seratonin and noradrenalin reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Databse Syst Rev 2005;(3):CD004742
   PubMedGoogle Scholar
• Andersson K, Chapple C, Cardozo L. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, et al., editors, Incontinence. 4th edition. Health Publications Ltd, Paris; 2009. p. 676-8
   Google Scholar
• Abrams P, Cardozo L, Fall M. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49
   PubMed Web of Science ®Google Scholar
• Sellers D, Chess-Williams R. Muscarinic agonists and antagonists: effects on the urinary bladder. Handb Exp Pharmacol 2012;208:375-400
   PubMedGoogle Scholar
• Andersson K, Wein A. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004;56:581-631
   PubMed Web of Science ®Google Scholar
• Lecci A, Maggi C. Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system. Regul Pept 2001;101:1-18
   PubMed Web of Science ®Google Scholar
• Murphy A, Krlin R, Goldman H. Treatment of overactive bladder: what is on the horizon? Int Urogynecol J 2013;24:5-13
   PubMed Web of Science ®Google Scholar
• Birder L, Kanai A, de Groat W, et al. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci USA 2001;98:13396-401
   PubMed Web of Science ®Google Scholar
• Birder L, Nakamura Y, Kiss S, et al. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci 2002;5:856-60
   PubMed Web of Science ®Google Scholar
• Brady C, Apostolidis A, Harper M, et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 2004;39:770-6
   Google Scholar
• Sharma S, Vij A, Sharma M. Mechanisms and clinical uses of capsaicin. Eur J Pharmacol 2013;720:55-62
   PubMed Web of Science ®Google Scholar
• Dmitrieva N, Berkley K. Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus. J Neurosci 2002;22:7147-53
   PubMed Web of Science ®Google Scholar
• Mukerjia G, Yiangoua Y, Agarwalb S, et al. Increased cannabinoid receptor 1-immunoreactive nerve fibers in overactive and painful bladder disorders and their correlation with symptoms. Urology 2010;75:1514
   Google Scholar
• Kavia R, Ridder D, Constantinescu C, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010;16:1349
   PubMed Web of Science ®Google Scholar
• Duramed. A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00685113?term=A+Clinical+Trial+to+Evaluate+the+Efficacy+and+Safety+of+DR-3001+in+Women+With+Overactive+Bladder.&rank=1 [Accessed 26 December 2013]
   Google Scholar
• Pharmaprojects. Oxybutynin Ring. Citeline Drug Intelligence (an informa business). 2013
   Google Scholar
• Teva. Form 20-F. U.S. Securities and Exchange Commission. 2012;40. Available from: http://www.sec.gov/Archives/edgar/data/818686/000119312513050510/d450498d20f.htm
   Google Scholar
• Duramed. A Safety Extension Study of DR-OXY-301. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00782769?term=A+Safety+Extension+Study+of+DR-OXY-301&rank=1 [Accessed 26 December 2013]
   Google Scholar
• Yamaguchi O, Homma Y. Long-term efficacy and safety of dose increase study of imidafenacin in patients with overactive bladder. Jpn Pharmacol Ther 2009;37:909-30; In Japanese
   Google Scholar
• Pharmaprojects. Afacifenacin. Citeline Drug Intelligence (an informa business). 2013
   Google Scholar
• TheraVida. TheraVida Announces Positive Results From a Phase 1 Trial of THVD-201 for Overactive Bladder at the 2011 Annual Congress of the European Association of Urology; 2011
   Google Scholar
• Flugel R, Paborji M, Duchin K, et al. Dose Escalation of a Muscarinic Antagonist with THVD-201, a Novel Combination Drug Product Containing TOLT. 43rd annual meeting of the ICS; 26 – 30 Augest 2013; Barcelona, Spain
   Google Scholar
• Pharmaprojects. Dexmecamylamine. Citeline Drug Intelligence (an informa business). 2013
   Google Scholar
• Merck. Form 10-Q. U.S. Securities and Exchange Commission. 2011;44. Available from: http://www.sec.gov/Archives/edgar/data/310158/000119312513084618/d438975d10k.htm
   Google Scholar
• Ohlstein E, von Keitz A, Michel M. A multicenter, double-blind, randomized, placebo-controlled trial of the beta3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 2012;62:834-40
   PubMed Web of Science ®Google Scholar
• Green S, Alon A, Ianus J, et al. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 2006;176:2535-40
   PubMed Web of Science ®Google Scholar
• Frenkl TL, Zhu H, Reiss T, et al. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol 2010;184:616-22
   PubMed Web of Science ®Google Scholar
• Haab F, Braticevici B, Krivoborodov G, et al. Efficacy and safety of repeated dosing of netupitant, a neurokinin-1 receptor antagonist, in treating overactive bladder. Neurourol Urodyn 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Maggi C, Barbanti G, Santicioli P, et al. Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex in humans. J Urol 1989;142:150-4
   PubMed Web of Science ®Google Scholar
• de Seze M, Wiart L, de Seze M. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol 2004;171:251-5
   PubMed Web of Science ®Google Scholar
• Pharmaprojects. REC-0422 Citeline Drug Intelligence (an informa business). 2013
   Google Scholar
• Pharmaprojects. UISH-001 Citeline Drug Intelligence (an informa business). 2013
   Google Scholar
• Kuang R, Bao WF, Zhao MH, et al. The anti-inflammatory effects of the n butanol extract of Xanthoceras sorbifolia Bunge. J Shenyang Yao Ke Da Xue Xue Bao 2001;18:53-6
   Google Scholar
• Lee J, Cannon T, Pruchnic R. The effects of periurethral muscle-derived stem cell injection on leak point pressure in a rat model of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2003;14:31
   PubMed Web of Science ®Google Scholar
• Chermansky C, Tarin T, Kwon D. Intraurethral muscle-derived cell injections increase leak point pressure in a rat model of intrinsic sphincter deficiency. Urology 2004;63:780
   PubMed Web of Science ®Google Scholar
• Carr L, Robert M, Kultgen P, et al. Autologous muscle derived cell therapy for stress urinary incontinence: a prospective, dose ranging study. J Urol 2013;189:595-601
   PubMed Web of Science ®Google Scholar
• Gavva N, Treanor J, Garami A, et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008;136:202-10
   PubMed Web of Science ®Google Scholar